McDermott Will & Emery represented REGENXBIO in the transaction. REGENXBIO closed its $1.8 billion strategic partnership with AbbVie to develop and commercialize RGX-314, a potential one-time...
This content is for Standard 1 Year members only. LoginJoin Now